{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:50:34Z","timestamp":1780473034300,"version":"3.54.1"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>This study aimed to evaluate the diagnostic accuracy of <jats:sup>18<\/jats:sup>F-Florastamin prostate-specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET\/CT) in detecting intermediate-risk prostate cancer and compare its performance with multiparametric magnetic resonance imaging (mpMRI).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods:<\/jats:title>\n            <jats:p>Fifty-nine patients with suspected intermediate-risk prostate cancer (prostate-specific antigen: 3\u201320\u00a0ng\/mL) were prospectively enrolled. All participants underwent examination with <jats:sup>18<\/jats:sup>F-Florastamin PET\/CT and mpMRI, with imaging results assessed using the PSMA-Reporting and Data System and Prostate Imaging-Reporting and Data System Version 2.1 scoring systems, respectively. Prostate biopsy served as the reference standard. Diagnostic metrics, including sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), accuracy, and area under the receiver operating characteristic curve (AUC), were calculated to compare the 2 modalities.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>PSMA PET\/CT demonstrated a sensitivity of 72.4%, specificity of 83.3%, and overall accuracy of 78%, with an AUC of 0.78 (95% CI: 0.67\u20130.89). Contrastingly, mpMRI showed a higher sensitivity (89.7%) but lower specificity (66.7%), achieving the same overall accuracy of 78% and an AUC of 0.78 (95% CI: 0.68\u20130.88). No statistically significant difference in AUC was observed between the 2 modalities (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.967). While PSMA PET\/CT offered higher specificity and PPV, reducing false-positive results, mpMRI excelled in sensitivity and NPV, minimizing false negatives.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>\n                                 <jats:sup>18<\/jats:sup>F-Florastamin PSMA PET\/CT demonstrated comparable diagnostic accuracy to mpMRI, with the added benefit of higher specificity. These findings suggest that PSMA PET\/CT could complement mpMRI in the diagnostic evaluation of intermediate-risk prostate cancer, enhancing patient stratification and aiding clinical decision-making.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000005798","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T05:00:09Z","timestamp":1746421209000},"page":"e352-e359","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Diagnostic Accuracy of PSMA-targeted 18F-Florastamin PET\/CT in Intermediate-risk Patients With Suspected Prostate Cancer"],"prefix":"10.1097","volume":"50","author":[{"given":"Jimin","family":"Yuei","sequence":"first","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4954-3543","authenticated-orcid":false,"given":"Wonho","family":"Jung","sequence":"additional","affiliation":[{"name":"Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7185-911X","authenticated-orcid":false,"given":"Kyoung Sook","family":"Won","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6203-4036","authenticated-orcid":false,"given":"Teak-Jun","family":"Shin","sequence":"additional","affiliation":[{"name":"Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2669-1885","authenticated-orcid":false,"given":"Byoung Je","family":"Kim","sequence":"additional","affiliation":[{"name":"Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1412-5360","authenticated-orcid":false,"given":"Mi Sun","family":"Choe","sequence":"additional","affiliation":[{"name":"Pathology, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1477-6606","authenticated-orcid":false,"given":"Hye Ra","family":"Jung","sequence":"additional","affiliation":[{"name":"Pathology, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5272-6362","authenticated-orcid":false,"given":"Byung-Hoon","family":"Kim","sequence":"additional","affiliation":[{"name":"Urology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae Won","family":"Kim","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"key":"R1-20250613","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"R2-20250613","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"R3-20250613","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.eururo.2013.05.049","article-title":"Systematic review of complications of prostate biopsy","volume":"64","author":"Loeb","year":"2013","journal-title":"Eur Urol"},{"key":"R4-20250613","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","article-title":"Prostate cancer, version 2.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Mohler","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"R5-20250613","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","article-title":"Screening and prostate-cancer mortality in a randomized European study","volume":"360","author":"Schroder","year":"2009","journal-title":"N Engl J Med"},{"key":"R6-20250613","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2013.03.030","article-title":"Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group","volume":"64","author":"Moore","year":"2013","journal-title":"Eur Urol"},{"key":"R7-20250613","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.urology.2009.04.102","article-title":"Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens","volume":"74","author":"Puech","year":"2009","journal-title":"Urology"},{"key":"R8-20250613","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"key":"R9-20250613","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2214\/AJR.13.11046","article-title":"Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis","volume":"202","author":"de Rooij","year":"2014","journal-title":"AJR Am J Roentgenol"},{"key":"R10-20250613","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1148\/radiol.13122233","article-title":"Prostate cancer localization using multiparametric MR imaging: comparison of Prostate Imaging Reporting and Data System (PI-RADS) and Likert scales","volume":"269","author":"Rosenkrantz","year":"2013","journal-title":"Radiology"},{"key":"R11-20250613","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"R12-20250613","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","article-title":"F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients","volume":"44","author":"Giesel","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R13-20250613","doi-asserted-by":"crossref","first-page":"10963","DOI":"10.1038\/s41598-020-67385-9","article-title":"Comparison of 68Ga-PSMA-617 PET\/CT with mpMRI for the detection of PCa in patients with a PSA level of 4\u201320 ng\/mL before the initial biopsy","volume":"10","author":"Li","year":"2020","journal-title":"Scientific Reports"},{"key":"R14-20250613","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00259-020-04883-y","article-title":"A microdose clinical trial to evaluate [(18)F]Florastamin as a positron emission tomography imaging agent in patients with prostate cancer","volume":"48","author":"Lee","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R15-20250613","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00330-023-10083-7","article-title":"Reliability and practicability of PSMA-RADS 1.0 for structured reporting of PSMA-PET\/CT scans in prostate cancer patients","volume":"34","author":"Grawe","year":"2024","journal-title":"Eur Radiol"},{"key":"R16-20250613","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2","volume":"76","author":"Turkbey","year":"2019","journal-title":"Eur Urol"},{"key":"R17-20250613","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: definition of grading patterns and proposal for a new grading system","volume":"40","author":"Epstein","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R18-20250613","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00259-012-2069-0","article-title":"[68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH","volume":"39","author":"Afshar-Oromieh","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R19-20250613","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol"},{"key":"R20-20250613","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3390\/ph10040077","article-title":"Procedures for the GMP-compliant production and quality control of [(18)F]PSMA-1007: a next generation radiofluorinated tracer for the detection of prostate cancer","volume":"10","author":"Cardinale","year":"2017","journal-title":"Pharmaceuticals (Basel)"},{"key":"R21-20250613","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s12149-023-01823-2","article-title":"Multi-timepoint imaging with PSMA-targeted [(18)F]F-Florastamin PET\/CT: lesion detection and comparison to conventional imaging","volume":"37","author":"Sheikhbahaei","year":"2023","journal-title":"Ann Nucl Med"},{"key":"R22-20250613","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.2967\/jnumed.117.204669","article-title":"Intraindividual comparison of (18)F-PSMA-1007 and (18)F-DCFPyL PET\/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: a pilot study","volume":"59","author":"Giesel","year":"2018","journal-title":"J Nucl Med"},{"key":"R23-20250613","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/bju.13540","article-title":"Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography\/computed tomography for preoperative lymph node staging in prostate cancer","volume":"119","author":"van Leeuwen","year":"2017","journal-title":"BJU Int"},{"key":"R24-20250613","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.eururo.2013.09.046","article-title":"EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013","volume":"65","author":"Heidenreich","year":"2014","journal-title":"Eur Urol"},{"key":"R25-20250613","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D\u2019Amico","year":"1998","journal-title":"JAMA"},{"key":"R26-20250613","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11307-016-0957-6","article-title":"PSMA-based [(18)F]DCFPyL PET\/CT Is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer","volume":"18","author":"Rowe","year":"2016","journal-title":"Mol Imaging Biol"},{"key":"R27-20250613","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1007\/s00259-017-3669-5","article-title":"Comparison of standard and delayed imaging to improve the detection rate of [(68)Ga]PSMA I&T PET\/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer","volume":"44","author":"Schmuck","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R28-20250613","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00259-018-4160-7","article-title":"Improved specificity with (68)Ga PSMA PET\/CT to detect clinically significant lesions \u201cinvisible\u201d on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology","volume":"46","author":"Donato","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R29-20250613","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/bju.13397","article-title":"(68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment","volume":"117","author":"van Leeuwen","year":"2016","journal-title":"BJU Int"},{"key":"R30-20250613","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s00259-017-3743-z","article-title":"Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence","volume":"44","author":"Uprimny","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R31-20250613","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/j.juro.2011.07.013","article-title":"Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds","volume":"186","author":"Turkbey","year":"2011","journal-title":"J Urol"},{"key":"R32-20250613","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1007\/s00330-015-4015-6","article-title":"Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference","volume":"26","author":"Vargas","year":"2016","journal-title":"Eur Radiol"},{"key":"R33-20250613","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.juro.2015.10.140","article-title":"The diagnostic performance of multiparametric magnetic resonance imaging to detect significant prostate cancer","volume":"195","author":"Thompson","year":"2016","journal-title":"J Urol"},{"key":"R34-20250613","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1007\/s00330-013-2795-0","article-title":"Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study","volume":"23","author":"Bratan","year":"2013","journal-title":"Eur Radiol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005798","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T12:00:39Z","timestamp":1749816039000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005798","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,5]]},"assertion":[{"value":"2024-12-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}